Testing effectiveness (Phase 2)Study completedNCT01435122What this trial is testingAxitinib in Advanced Carcinoid TumorsWho this might be right forCarcinoid Tumor H. Lee Moffitt Cancer Center and Research Institute 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06577961What this trial is testingVorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC PatientsWho this might be right forKidney CancerRCCRenal Cell Carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences 37
Testing effectiveness (Phase 2)UnknownNCT00039169What this trial is testingBAY 59-8862 in Treating Patients With Advanced Kidney CancerWho this might be right forKidney Cancer Theradex
Testing effectiveness (Phase 2)Study completedNCT00003105What this trial is testingCombination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder CancerWho this might be right forBladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter Memorial Sloan Kettering Cancer Center 30
Large-scale testing (Phase 3)Active Not RecruitingNCT03793166What this trial is testingImmunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE StudyWho this might be right forClear Cell Renal Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Malignant Neoplasm in the Lymph Nodes+6 more National Cancer Institute (NCI) 1,175
Testing effectiveness (Phase 2)Study completedNCT00045279What this trial is testingPEG-Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerWho this might be right forKidney Cancer Memorial Sloan Kettering Cancer Center
Early research (Phase 1)Study completedNCT00049296What this trial is testingThalidomide and Docetaxel in Treating Patients With Advanced CancerWho this might be right forCancer Case Comprehensive Cancer Center 26
Large-scale testing (Phase 3)Study completedNCT00492986What this trial is testingAn Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell CarcinomaWho this might be right forCarcinoma, Renal Cell Bayer 1,150
Testing effectiveness (Phase 2)Active Not RecruitingNCT04561362What this trial is testingStudy BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesWho this might be right forUrinary Bladder NeoplasmTriple Negative Breast NeoplasmsHormone Receptor Positive, HER2-negative Neoplasms+5 more BicycleTx Limited 329
Not applicableStudy completedNCT06345183What this trial is testingReal-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) PatientsWho this might be right forAdvanced Renal Cell Carcinoma (aRCC) Bristol-Myers Squibb 327
Testing effectiveness (Phase 2)Ended earlyNCT02626754What this trial is testingA Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian PopulationWho this might be right forRenal Cell Carcinoma vghtpe user 13
Not applicableEnded earlyNCT01195649What this trial is testingAdvanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based TherapyWho this might be right forCarcinoma, Renal Cell Bayer 11
Large-scale testing (Phase 3)Study completedNCT00003376What this trial is testingTwo-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the UrotheliumWho this might be right forBladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer Eastern Cooperative Oncology Group 330
Not applicableUnknownNCT03896958What this trial is testingThe PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)Who this might be right forCancer, All TypesCancer of LiverCancer of Stomach+42 more SpeciCare 1,000
Not applicableEnded earlyNCT04106167What this trial is testingLong-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular ImmunotherapyWho this might be right forAdvanced Solid TumorLymphomaGastric Cancer+15 more Fate Therapeutics 20
Post-approval studies (Phase 4)Study completedNCT02555748What this trial is testingTherapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell CarcinomaWho this might be right forMetastatic Renal Cell Cancer Institut Claudius Regaud 47
Early research (Phase 1)Study completedNCT01155258What this trial is testingTemsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid TumorsWho this might be right forExtensive Stage Small Cell Lung CancerHereditary ParagangliomaMale Breast Cancer+45 more University of Southern California 19
Large-scale testing (Phase 3)Study completedNCT01064310What this trial is testingPatient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney CancerWho this might be right forCarcinoma, Renal Cell Novartis Pharmaceuticals 169
Early research (Phase 1)Study completedNCT01169584What this trial is testingSafety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric PatientsWho this might be right forNeuroblastomaRhabdomyosarcomaLymphoma+2 more Jennerex Biotherapeutics 6
Not applicableEnded earlyNCT01598038What this trial is testingRelation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell CarcinomaWho this might be right forRenal Cell Carcinoma Centre Francois Baclesse 41